Although both treatments are highly effective, they work differently in the body and may lead to different outcomes in terms of weight loss, side effects, and cost
If no USP monograph existsas is in the case of semaglutideFDA does not require the development of a new monograph for approval, but applicants should work with USP to create a monograph through the USP Pending Monograph Process (USP-PMP)
The current evidence does not support a direct mechanism by which semaglutide would cause joint inflammation or damage
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
In pharmacology, bioavailability refers to the percentage of a drug that reaches systemic circulation unchanged
Who should consider semaglutide with niacinamide Not everyone needs niacinamide in their compound